中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

68 records (took 0.021 seconds)

    COMPOSITIONS AND METHODS FOR TREATMENT OF NAFLD AND NASH AND RELATED DYSLIPIDEMIAS
    1.
    发明申请
    COMPOSITIONS AND METHODS FOR TREATMENT OF NAFLD AND NASH AND RELATED DYSLIPIDEMIAS 有权

    公开(公告)号：US20250134858A1

    公开(公告)日：2025-05-01

    申请号：US18836268

    申请日：2023-02-10

    Applicant: EpicentRx, Inc.

    Inventor： Scott CAROEN ,  Tony REID ,  Bryan ORONSKY

    IPC: A61K31/397 ,  A61K31/155 ,  A61K31/355 ,  A61K31/465 ,  A61K31/616 ,  A61K31/7088 ,  A61K35/14 ,  A61K35/18 ,  A61K36/062 ,  A61K39/395 ,  A61K45/06 ,  A61P1/16

    Abstract: Compositions and methods for preventing or treating a disease or a disorder associated with dyslipidemia are provided. This includes prevention or treatment of non-alcoholic fatty liver disease (NAFLD) and/or non-alcoholic steatohepatitis (NASH). The method comprises administering an effective amount of RRx-001, or a pharmaceutically acceptable salt thereof, to the subject in need thereof to reduce at least one factor of the disease or the disorder, such as a hepatic steatosis score, a serum ALT level, a fibrosis marker, a serum AST level, a hepatic level of cholesterol, a hepatic level of triglycerides, insulin resistance, hyperinsulinemia, a serum NLRP3 level, an oxidative or inflammatory stress marker in the subject, and/or a marker associated with low-density lipoprotein (LDL). In some embodiments, the effective amount of RRx-001, or the pharmaceutically acceptable salt thereof, is administered in a pharmaceutical composition that includes a blood product and/or an agent.

    MEDICATION INFUSION DEVICES, SYSTEMS, AND METHODS
    5.
    发明申请
    MEDICATION INFUSION DEVICES, SYSTEMS, AND METHODS 有权

    公开(公告)号：US20210178050A1

    公开(公告)日：2021-06-17

    申请号：US17119423

    申请日：2020-12-11

    Applicant: EpicentRx, Inc.

    Inventor： Bryan T. Oronsky ,  Scott Caroen

    IPC: A61M1/36 ,  A61M1/38

    Abstract: Devices, systems, and methods for medication infusion are described herein. In some embodiments, a system includes a patient access subassembly, a first fluid reservoir, a second fluid reservoir, and an assembly. The assembly can have a first configuration in which the patient access subassembly is in fluid communication with the first fluid reservoir via a first tube, a second configuration in which the first fluid reservoir is in fluid communication with the second fluid reservoir, and a third configuration in which the first fluid reservoir is in fluid communication with the patient access subassembly via a second tube, the first fluid reservoir fluidically isolated from the first tube in the third configuration.

    IMMUNOMODULATORY FUSION PROTEINS
    7.
    发明申请
    IMMUNOMODULATORY FUSION PROTEINS 审中-公开

    公开(公告)号：US20200223901A1

    公开(公告)日：2020-07-16

    申请号：US16651079

    申请日：2018-09-27

    Applicant: EpicentRx, Inc.

    Inventor： Christopher Larson ,  Tony R. Reid ,  Bryan T. Oronsky

    IPC: C07K14/715 ,  C07K14/54 ,  C12N15/62 ,  A61P35/00

    Abstract: Provided is a fusion protein, e.g., a cytokine receptor fusion protein, e.g., an IL-10 trap, with a novel linker sequence to permit the fusion protein to functionally optimally, e.g., to permit a cytokine receptor portion of a cytokine receptor fusion protein to bind optimally to its target cytokine. The fusion protein, or an expression vector encoding for the fusion proteins, can be used to treat cell proliferative diseases and disorders, including certain forms of cancer and inflammatory disorders.

Patent Agency Ranking